18/07/2019: Pharegis implemented optimized procedures for state registration of pharmaceuticals in Eurasian Economic Union.
20/06/2019: Pharegis updated timelines and practical approaches for Russian and EEU GMP inspection applications and procedures.
03/04/2019: Renewed general monographs of Russian state pharmacopeia XIV ed. have been analyzed.
Global industry news
FDA study finds fear and distrust among front-line workers and minority groups around COVID-19 vaccines
CDC working with Warp Speed, local jurisdictions on nationwide COVID-19 vaccine plan: official
Moderna, now wrapped on phase 3 enrollment, touts diversity of vaccine trial participants
+7 495 442 37 85
+7 985 908 58 18
Registration of Medical Drugs in Russia
Registration of Pharmaceuticals in Russia
Registration of Pharmaceutical Dossier Variations in Russia
Registration of Pharmaceuticals in CIS
Clinical Studies in Russia
Clinical Studies for Registration of Pharmaceuticals in Russia
International Phase III Clinical Studies
Phase I, Phase II (IIa, IIb) Clinical Studies
Preclinical Studies in Russia
Preclinical Studies for Registration of Pharmaceuticals in Russia
Preclinical Studies for Registration of Biopharmaceuticals in Russia
In Vitro Preclinical Studies in Russia
Regulatory Consulting in Russia and EEU
Certification of Medical Drugs and Medical Devices in Russia
Registration of Medical Devices in Russia
Russian GMP inspection of pharmaceutical manufacturers
Regulatory Events Russia
Russian Regulatory News
You are here:
Pharegis LLC / ООО "Фареджис"
3-1 Begovaya str. ("NordStar Tower", 31st flr), Moscow, Russia 125284
Legal & postal address:
11A-11 Cherkizovskaya B. str., Moscow, Russia 107392
TAX ID (TIN): 7718278100
+7 495 442 37 85 9am-6pm GMT+3
+ 7 495 442 37 85
+ 7 985 908 58 18
Send an Email
Send a copy to yourself
SHARE THIS BY:
Create an account
Forgot your username?
Forgot your password?
Drugs.com - New Drug Approvals
FDA Approves Veklury (remdesivir) for the Treatment of COVID-19
FDA Approves Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) Antibody Cocktail for Ebola (Zaire Ebolavirus)
FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma
FDA Approves Alkindi Sprinkle (hydrocortisone oral granules) for Pediatric Adrenocortical Insufficiency
Simponi Aria (golimumab) Approved by the FDA for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
News and press releases
10th ESVAC report shows continued decrease in sales of veterinary antibiotics , , 21/10/2020
EMA virtual conference: 25 years of advancing public and animal health, , 19/10/2020
First long-acting injectable antiretroviral therapy for HIV recommended for approval, CHMP, 16/10/2020
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2020, CHMP, 16/10/2020
Drugs.com - Clinical Trials
An Open Letter from Merdad Parsey, Chief Medical Officer, Gilead Sciences
October 22, 2020 -- In less...
ViiV Healthcare Announces Analysis Showing no Antiretroviral Therapy Interruptions Due to COVID-19 Across its Clinical Development Programme for Investigational, Long-Acting Cabotegravir and Rilpivirine
21 October 2020 -- ViiV...
Merck Announces Positive Topline Results from Two Additional Phase 3 Adult Studies Evaluating V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine
FDA Grants Fast Track Designation for ASP0367/MA-0211, a Selective PPARδ Modulator being Developed for the Treatment of Primary Mitochondrial Myopathies
TOKYO, Oct. 20, 2020...
PharmaTimes: PharmaTimes Website RSS
STORM Therapeutics’ METTL3 inhibitor moves closer to the clinic
Pharming’s APDS drug scores EU orphan status
Valneva bags positive phase II results for Lyme disease vaccine
Epsilogen awarded £1m grant from Innovate UK
Asthma fund launched to support development and adoption of new technologies
Terms of Service
Sample Non-Disclosure Agreement